Mr Iain Ross is an experienced multinational pharmaceutical and biotechnology executive and board member, and is currently Chairman of Silence Therapeutics plc (LSE & NASDAQ:SLN), ReNeuron Group plc (LSE:RENE) and BiVictriX Therapeutics plc (LSE:BVX).
During his career, Mr Ross has held senior positions at multinational companies, Sandoz AG, Hoffman La Roche, and Celltech Group PLC and been a Chairman, CEO and Director of several biotech companies. He is a qualified Chartered Director and former Vice Chairman of the Council of Royal Holloway, London University.
Mr Ross was appointed as a director of the Company in July 2015 and is considered to be an independent director. He is a member of the Audit, Risk and Governance Committee and a member of the Remuneration and Nominations Committee.